Cabazitaxel was approved by the FDA in 2010 as the brand name Jetvana, for the treatment of advanced prostate cancer. Cabazitaxel, CAS number 183133-96-2, is an anti-cancer medication that is typically prescribed alongside the steroid prednisone. Patients that have become resistant to docetaxel or other cancer treatments may find success with cabazitaxel. Adverse effects are expected, and may include low blood and platelet counts, vomiting and nausea, weakness, fever and hair loss. Despite the potential of negative side effects, cabazitaxel is a viable option for patients with metastatic hormone-refractory prostate cancer.
Approved in June of 2010, cabazitaxel proved efficacious in results from a randomized, international trial of 755 patients, composed of patients with metastatic hormone-refractory prostate cancer. The patients in this study were previously treated with docetaxel-containing regimens and assigned to randomly receive cabazitaxel 25 mg/m2 intravenously every three weeks in combination with prednisone 10 mg per day, or mitoxantrone 12 mg/m2 intravenously every three weeks in combination with prednisone 10 mg per day. Treatment continued until the advent of disease progression, death, unacceptable toxicity, or a completion of 10 cycles of therapy.
The median survival for patients dosed with was cabazitaxel was 15.1 months, compared to a 12.7 months survival for the patients treated with mitoxantrone. Androgen-independent prostate cancer, which is what metastatic hormone-refractory prostate cancer is, presents itself as a disease that includes a varied group of patients. Historically, despite castrate levels of testosterone, patients who present with metastatic disease typically manifest their disease progression within 12 to 18 months, and have a median survival of two to three years. Continued research needs to be done to glean additional treatments for this diverse group of patients. LGM Pharma provides the API cabazitaxel for your research and development needs, and offers continued support to clients throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.